Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DCAF8L1 (DDB1- and CUL4-associated factor 8-like protein 1) is a member of the WD repeat protein family, functioning as a substrate receptor within the CRL4 E3 ubiquitin ligase complex. It directly binds to BRCA1 and BARD1, targeting them for ubiquitin-dependent proteasomal degradation and thereby negatively regulating their protein levels. DCAF8L1 plays a key role in DNA damage repair through its modulation of the BRCA1 pathway, impacting homologous recombination repair and cellular response to DNA-damaging agents. Overexpression of DCAF8L1 in breast cells results in reduced BRCA1/BARD1 abundance, increased genomic instability, and heightened sensitivity to genotoxic stress. This protein is encoded by an intronless, X-linked retrocopy gene, and does not have a clear ortholog in mice. Its function links the ubiquitin-proteasome system to cancer biology, particularly breast cancer, by contributing to tumorigenesis when dysregulated
Drugs that target DCAF8L1, if discovered, would likely function by modulating ubiquitination/degradation of BRCA1/BARD1, impacting homologous recombination DNA repair and genomic stability
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DDB1- and CUL4-associated factor 8-like protein 1 (DCAF8L1).